A short recovery milestone is not interchangeable with the patient’s broader postoperative experience.
What the study found
A meta-analysis combined quality-of-recovery questionnaires from thirteen studies. Remimazolam and propofol did not clearly differ on the pooled early questionnaire scores, despite differences in some immediate induction and awakening measures.
Patient-reported recovery was measured later
The synthesis included thirteen studies and 1,418 patients. Most used the QoR-15 questionnaire; the remainder used QoR-40. The day-one pooled standardized difference was near zero, with substantial heterogeneity. Remimazolam was associated with recovery of consciousness about 1.6 minutes earlier on average, but that immediate milestone did not translate into a clear pooled questionnaire advantage. Both time scale and outcome definition belong in the conclusion.
Limits of interpretation
The review combined different questionnaires and surgical settings, with heterogeneity. A null pooled score is not proof that all dimensions or individual patients had identical recovery. Several secondary outcomes addressed different time windows.
Implications for case review
State which recovery measure supports a comparison. Eye opening, extubation, pain and a next-day questionnaire each answer a narrower question. The review cannot establish full functional recovery from an early awakening time or show that one drug is universally preferable for every patient.
Source and related reading
Source: PMC11409698, supplied full-text paper. Findings are paraphrased; forensic implications are an interpretation.
Related: Midazolam–Ketamine Pediatric Colonoscopy Had More Recovery Events Than Propofol–Fentanyl.
Leave a Reply